Pancreatic Cancer Stocks
Biotechnology and medical device firms in this sector focus on the high-unmet-need oncology niche of pancreatic ductal adenocarcinoma, characterized by late-stage diagnosis and a dense stroma that inhibits traditional drug delivery.
As of Oct 23, 2026, Pancreatic Cancer has 17 US-listed companies worth $43B combined. The median member moved -1.5% over the past week; ELTX led at +21.8% and SLBT trailed at -24.8%.
Companies in Pancreatic Cancer
- RVMD – Revolution Medicines Inc, $40.2B
- SLBT – SL Science Holding Limited Ordinary Shares, $869M
- CADL – Candel Therapeutics Inc, $709M
- YDES – YD Bio Ltd, $477M
- IMRX – Immuneering Corp, $255M
- TLSI – TriSalus Life Sciences Inc., $250M
- ONCY – Oncolytics Biotech Inc, $71.8M
- RNXT – RenovoRx Inc, $52.4M
- ELTX – Elicio Therapeutics Inc., $50.5M
- RNAZ – Transcode Therapeutics Inc, $30.1M
- ACTU – Actuate Therapeutics, Inc. Common stock, $14.5M
- TOVX – Theriva Biologics Inc., $9.9M
- XBIO – Xenetic Biosciences Inc, $5.2M
- AMIX – Autonomix Medical, Inc. Common Stock, $4.9M
- PMCB – PharmaCyte Biotech Inc, $3.7M
- PPBT – Purple Biotech, $2.5M
- PBLA – Panbela Therapeutics Inc, $14,564